QuiaPEG Pharmaceuticals AB – improved versions of existing drugs

In 2018, QuiaPEG signed a non-exclusive Licensing and Commercialization Agreement with Xiamen SinoPEG Biotech Ltd for the manufacturing, marketing and sales of products and services based on QuiaPEG´s Uni-Qleaver® technology. SinoPEG is headquartered in Xiamen, China, where a state-of-the-art facility provides manufacturing of PEGs and the Uni-Qleaver®.
QuiaPEG offers licenses to companies interested in evaluating reversible PEGylation for their own drug development projects. We are also interested in discussing potential partnering opportunities regarding our in-house development projects.
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
+46 (0) 70 693 12 53

User terms & privacy policy
Send a message